One-third of patients diagnosed with throat cancer are infected with human papillomavirus (HPV), mostly associated with cervical cancer, reports the Journal of Clinical Oncology
O fa'ama'i pipisi e maua i le papillomavirus o le tagata (HPV) o lo'o sili ona taatele i le lalolagi. O le siama e tele lava ina feaveai i feusuaiga e ala i fesootaiga tuusao o le mucous membrane o le itutinosa, ae faapea foi le paʻu o loo siomia ai. Ua fuafuaina e le Faalapotopotoga o le Soifua Maloloina a le Lalolagi (WHO) e oo atu i le 80 pasene. O tagata fa'afeusuaiga e atia'e fa'ama'i HPV i se taimi o latou olaga. Mo le tele o i latou, e le tumau. Ae ui i lea, i se pasene patino e avea ma taimi masani, lea e faʻateleina ai le lamatiaga o le atiaʻe o ituaiga kanesa eseese.
Of the more than 100 known subtypes (so-called serotypes) of the human papillomavirus (HPV), several are carcinogenic. There are especially two subtypes – HPV16 and HPV18, which are responsible for almost 70 percent. cases of cervical cancer.
Ua fa'atatau e le au popoto a le WHO o fa'ama'i pipisi o le HPV e nafa ma le toeitiiti 100 pasene. mataupu o le kanesa faa'au'auna, ma le faaopoopoga mo le 90 pasene. mataupu o le kanesa rectal, 40 pasene mataupu o le kanesa o totoga i fafo - e pei o le vulva, va'a ma le penis, ae faapena foi mo se pasene patino o ulu ma ua, e aofia ai le 12% mataupu o le kanesa o le larynx ma pharynx ma approx. 3 pasene. kanesa o le gutu. O lo'o iai fo'i su'esu'ega o lo'o fa'ailoa mai ai le a'afia o le siama i le atina'eina o le kanesa o le susu, mama ma le prostate.
O su'esu'ega talu ai nei ua fa'ailoa mai ai le fa'atupula'ia o le fa'a'i ma le kanesa o le laryngeal e feso'ota'i ma fa'ama'i HPV. E o'o mai i le taimi nei, o le fa'aaogaina o le 'ava mālosi ma le ulaula o lo'o manatu i ai o ni fa'alavelave sili ona taua mo nei kanesa. Ua masalomia e saienitisi o le faateleina o le aafia o le HPV i le atinaʻeina o nei kanesa e fesoʻotaʻi ma le tele o le saolotoga o feusuaiga ma le lauiloa o feusuaiga tautala.
Ina ia tofotofoina le sootaga i le va o le HPV ma le kanesa o nisi o kanesa o le ulu ma le ua, na faia ai e saienitisi mai se vaega faavaomalo se suesuega o 638 gasegase o loo mafatia mai ia i latou, e aofia ai ma le kanesa o le gutu gutu (180 gasegase), kanesa o le oropharynx (135 gasegase) , kanesa o le pharynx pito i lalo / larynx (247 gasegase). Na latou suʻesuʻeina foi tagata mamaʻi e maua i le kanesa o le esophage (300 tagata). Mo faʻatusatusaga, 1600 tagata soifua maloloina na faʻataʻitaʻiina. O i latou uma na auai i se suʻesuʻega umi a Europa i le va o le olaga ma le lamatiaga o le kanesa - European Prospective Investigation Into Cancer and Nutrition.
O fa'ata'ita'iga toto na foa'i uma i le amataga o le su'esu'ega a'o latou soifua maloloina sa su'esu'eina mo fa'ama'i i polotini HPV16 fa'apea fo'i ma isi fa'ama'i pipisi o le papillomavirus tagata e pei ole HPV18, HPV31, HPV33, HPV45, HPV52, ma le HPV6 ma le HPV11. le mafua'aga sili ona taatele ole ma'i ae fa'alavelave fa'alavelave (e ta'ua o le itutino), ma e seasea tupu ai le kanesa vulvar.
The cancer samples were on average six years old, but some were even more than 10 years old before diagnosis.
It turned out that as many as 35 percent. Oropharyngeal cancer patients have been found to have antibodies to an important protein of HPV 16, abbreviated as E6. It turns off the protein responsible for inhibiting the neoplastic process in cells and thus contributes to its development. The presence of antibodies to the E6 protein in the blood usually indicates the development of cancer.
For comparison, in the control group the percentage of people with antibodies in the blood was 0.6%. There was no relationship between their presence and other head and neck tumors included in the study.
The researchers emphasized that the relationship between the presence of these antibodies and oropharyngeal cancer existed even for patients from whom a blood sample was obtained more than 10 years before cancer diagnosis.
Interestingly, among patients with oropharyngeal cancer and the presence of anti-HPV16 antibodies, a lower percentage of deaths due to various causes was found than among patients without antibodies. Five years after the diagnosis, 84 percent were still alive. people from the first group and 58 percent. the other.
These surprising results provide some evidence that HPV16 infection may be a significant cause of oropharyngeal cancer, comments co-author Dr. Ruth Travis of the University of Oxford.
Sara Hiom from the Cancer Research UK foundation said in an interview with the BBC that HPV viruses are very widespread.
Having sex safely may lower the risk of contracting an infection or passing HPV to someone, but condoms will not completely protect you from infection, she noted. It is known that the virus present on the skin in the genital area can also be a source of infection.
Na faamamafa e Hiom e le o iloa pe o tui o loo faaaogaina i le taimi nei e puipuia ai le kanesa o le faa'autagata i teine talavou (o se tasi o ia mea ua faamaonia foi mo tama e puipuia ai totoga o le itutinosa ma le kanesa penile) e mafai ona faaitiitia ai le lamatiaga o le kanesa oropharyngeal. Afai e faʻamaonia e le suʻesuʻega, o le a faʻaalia e mafai ona faʻaaogaina lautele i le puipuia o neoplasms leaga. (PAP)
jjj / agt /